Research update: November 12, 2026. The newest peer-reviewed retatrutide paper identified for this update was published in the New England Journal of Medicine on November 8. It reports phase 3 research in adults with painful knee osteoarthritis and obesity. The central finding is encouraging, but a pain improvement is not evidence of cartilage regeneration or a cure.
Scope: This is an educational review of clinical research, not treatment advice. Retatrutide remains investigational. The medicine used in a controlled clinical trial is not interchangeable with independently supplied laboratory research material.
What is new in the November retatrutide study?
The November 8 NEJM paper by Schnitzer and colleagues brings together findings from TRIUMPH-4 and TRIUMPH-1-OA. Both evaluated retatrutide against placebo in adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27. Eli Lilly funded the research. The trials examined pain and body weight, rather than whether the joint had been structurally repaired.
TRIUMPH-4: read the 68-week results with the comparator
The ACR trial abstract reports the following efficacy-estimand results. An estimand defines the treatment effect being estimated, including how treatment interruptions or other events are handled. These results should not be combined indiscriminately with figures calculated using another analysis approach.
| Change at week 68 | Retatrutide 9mg trial group | Retatrutide 12mg trial group | Placebo |
|---|---|---|---|
| WOMAC pain score | -4.48 points | -4.41 points | -2.43 points |
| Body weight | -26.4% | -28.7% | -2.1% |
WOMAC is an osteoarthritis questionnaire. In this study, its pain scale runs from 0 to 10, with higher scores indicating worse pain. The trial-group labels describe the study, not a recommended regimen. Placebo participants also improved, so the difference between groups matters more than a treatment group’s change alone.
What the 80-week companion research adds
The TRIUMPH-1-OA conference abstract presented November 10 describes sustained pain and physical-function improvements through week 80. Reported body-weight changes ranged from -18.6% to -28.7% across retatrutide groups, compared with -1.5% with placebo. This is companion evidence from a distinct trial population, not an extra follow-up measurement of TRIUMPH-4.
Safety findings belong beside the benefits
The journal abstract reports that serious adverse events were more frequent with retatrutide than placebo in both trials; gastrointestinal events were the most common adverse events. The 80-week conference abstract also reports fewer gastrointestinal events and fewer adverse-event discontinuations in its lower-dose group. A favorable average result does not describe every participant’s experience or establish that a treatment is appropriate for an individual.
What these findings do not establish
- Reduced pain does not by itself demonstrate cartilage repair or reversal of osteoarthritis.
- These studies do not establish the same outcomes in people outside their enrollment criteria.
- Clinical findings cannot verify the identity, purity or biological activity of an unrelated research sample.
For the underlying distinctions, read our guides to retatrutide receptor assays, peptide identity evidence and purity versus peptide content. The practical lesson is to keep the clinical endpoint, the analysis method and the tested material clearly identified.
Source note: This update uses the journal abstract and the two original ACR conference abstracts linked above. Full journal text and supplementary safety tables were not accessible during preparation; detailed safety rates have therefore not been reproduced. The image is an editorial illustration, not a photograph from either trial.